ClinicalTrials.gg
RecruitingNCT05124808iGDMUpdated Oct 16, 2026

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

An interventional study of Intensive glycemic targets and Standard glycemic targets in Gestational Diabetes, Pregnancy, High Risk and Overweight and Obesity, sponsored by Indiana University. Recruiting at 5 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Oct 16, 2026Primary completion movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
828
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Planned enrollment
14th of 194
828 · median 80
Started
2022
with 9 others
No phase
154 of 251
31 open now
Primary completion
2026-12
later than 27 of 64 live
Registered
171st of 251
by date
Lead sponsor
5 of 251
Indiana University

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 14th largest by planned enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2022, is one of 154 with no phase, reaches primary completion later than 27 of the 64 other live ones, and was the 171st registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.

Read the detailed description

The prevalence of both obesity and gestational diabetes mellitus (GDM) have increased, and each is associated with adverse perinatal outcomes including fetal overgrowth, neonatal morbidity, hypertensive disorders of pregnancy, and cesarean delivery. Women with GDM who are also overweight and obese have higher rates of pregnancy complications when compared to normal weight women with GDM, which may occur in part due to suboptimal glycemic control. The current recommendations for glycemic targets in pregnant women with diabetes are not rigorously defined, and they far exceed the mean fasting (70.9 ±7.8 mg/dL) and 1 hour post- prandial (108.9 ± 12.9 mg/dL) glucose values in pregnant women without GDM. Our prior work demonstrated that use of intensive (fasting \<90, 1 hr post-prandial \<120 mg/dL) compared to standard (fasting \<95 mg/dL, 1 hr post-prandial \<140 mg/dL) glycemic targets resulted in improved glycemic control without increasing the risk for hypoglycemia. The Intensive Glycemic Targets in Overweight and Obese Women with Gestational Diabetes Mellitus: A Multicenter Randomized Trial (iGDM Trial) is a large, pragmatic randomized clinical trial designed to investigate the impact of intensive versus standard glycemic targets on perinatal outcomes in women with GDM who are overweight and obese. During the 5-year project period, a multidisciplinary team of investigators from 4 medical centers representing regions of the U.S. with high rates of obesity will randomize 828 overweight and obese women with GDM to either intensive or standard glycemic targets. The specific aims of this project are: 1) Determine the effectiveness of intensive glycemic targets in reducing the risk for neonatal composite morbidity and large for gestational age birthweight in overweight and obese women with GDM, 2) Assess the safety of intensive glycemic targets as measured by the frequency of maternal hypoglycemia in overweight and obese women with GDM, and 3) Evaluate the cost-effectiveness of intensive glycemic control compared with standard glycemic control as measured by the incremental cost per case of neonatal morbidity and LGA birth weight prevented and per Quality-adjusted Life-year. The expected outcome of this study is high-quality evidence on the effectiveness, safety, and cost-effectiveness of intensive glycemic targets in reducing adverse perinatal outcomes among overweight and obese women with GDM. If proven effective, use of intensive glycemic targets in overweight and obese women with GDM will have an important positive impact on the health of these high risk women and their infants.

03

Conditions studied

  • Gestational Diabetes
  • Pregnancy, High Risk
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women between the ages of 18-45
  • Singleton gestation
  • Gestational age between 12 0/7-32 6/7 weeks' gestation with gestational diabetes diagnosed during this time frame using either a 50g 1-hr GCT ≥200 mg/dL or two or more abnormal values on a 100g OGTT using the Carpenter-Coustan Criteria
  • Overweight or obese at the first prenatal visit (BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian Americans)

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to provide
  • Inability to communicate with members of the study team, despite the presence of an interpreter
  • Planned delivery at a non-study affiliated hospital
  • Known renal disease with a baseline creatinine >1.5 mg/dL
  • Significant fetal anomalies diagnosed prior to study enrollment (these will include anomalies such as gastroschisis, spina bifida, complex congenital heart disease, or serious karyotypic anomalies that may lead to early delivery or increased risk of neonatal death)
  • Oral or IV/IM use within 7 days of study enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
828 participants (estimated)

Study arms

  • Experimental
    Intensive glycemic targets

    Participants in this arm will target a fasting blood glucose of \<90 mg/dL and 1 hour post-prandial blood glucose values \<120 mg/dL.

    Other: Intensive glycemic targets

  • Active comparator
    Standard glycemic targets

    Participants in this arm will target a fasting blood glucose of \<95 mg/dL and 1 hour post-prandial blood glucose values \<140 mg/dL.

    Other: Standard glycemic targets

Interventions

  • OtherIntensive glycemic targets

    Fasting blood glucose \<90 mg/dL, 1 hour post-prandial blood glucose \<120 mg/dL

  • OtherStandard glycemic targets

    Fasting blood glucose \<95 mg/dL, 1 hour post-prandial blood glucose \<140 mg/dL

06

What researchers measure

Primary outcomes

  1. Number of participants with composite neonatal morbidity

    Composite of large for gestational age birth weight, neonatal hypoglycemia, neonatal jaundice, and neonatal respiratory distress syndrome

    Time frame: Within 7 days of delivery

Secondary outcomes

  1. Number of participants with large for gestational age birth weight

    ≥90th percentile birth weight for gestational age, based on US birth weight normograms

    Time frame: Birth

  2. Number of participants with neonatal hypoglycemia

    Blood glucose \<40 mg/dL in the 1st 24 hours of life

    Time frame: Within 24 hours of delivery

  3. Number of participants with neonatal jaundice

    Documentation of need for phototherapy

    Time frame: Within 7 days of delivery

  4. Number of participants with respiratory distress syndrome

    Signs of respiratory distress (tachypnea, grunting, nasal flaring, cyanosis) with an oxygen requirement within the first 24 hours of life and the presence of radiologic chest findings of hypoaeration and reticulogranular infiltrates or those needing immediate intubation for respiratory distress syndrome

    Time frame: Within 7 days of delivery

  5. Maternal hyperglycemia

    Percent of maternal glucose values ≥120 and ≥140 mg/dL from randomization through delivery

    Time frame: From randomization to delivery

  6. Early maternal glycemic levels

    Mean fasting and post-prandial values in the 7 days after randomization

    Time frame: 7 days after randomization

  7. Pre-delivery maternal glycemic levels

    Mean fasting and post-prandial values in the 14 days prior to delivery

    Time frame: 14 days prior to delivery

  8. Glycemic levels during study enrollment

    Mean fasting and post-prandial glucose values from study enrollment until delivery

    Time frame: Up to 29 weeks

  9. Episodes of maternal hypoglycemia

    Percent of all glucose values \<60 mg/dL

    Time frame: From randomization to delivery

  10. Number of episodes of symptomatic maternal hypoglycemia

    Number of episodes of symptomatic hypoglycemia, episodes of symptomatic hypoglycemia requiring assistance

    Time frame: From randomization to delivery

  11. Number of participants with hypertensive disorders of pregnancy (gestational hypertension and pre-eclampsia)

    Gestational hypertension • Requires systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg on two occasions at least for hours apart after 20 weeks of gestational in a woman with a previously normal blood pressure Pre-eclampsia * Requires systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg on two occasions at least for hours apart after 20 weeks of gestational in a women with a previously normal blood pressure and at least one of the following:69 * Proteinuria (≥300 mg/24 hour timed collection, protein/creatinine ratio \>0.3, or 2+ proteinuria on dipstick) * Thrombocytopenia (platelets\<100,000) * Elevated blood concentrations of liver transaminases to twice normal concentration * Creatinine \>1.1 mg/dL or a doubling of the serum creatinine concentration * Headache, blurry vision, or epigastric/RUQ pain * Pulmonary edema OR Systolic blood pressure of 160 mm Hg or diastolic blood pressure of 110 mg Hg or more

    Time frame: From randomization up to 30 days after delivery

  12. Number of participants with small for gestational age birth weight

    ≤10th percentile birth weight for gestational age, based on US birth weight normograms

    Time frame: Birth

  13. Number of participants with cesarean delivery

    Cesarean delivery for any indication

    Time frame: Delivery

  14. Number of participants with preterm birth <37 weeks

    Gestational age at delivery \<37 0/7 weeks (spontaneous or indicated)

    Time frame: Delivery

  15. Number of participants with shoulder dystocia

    Documentation in the medical record of failure to deliver the fetal shoulder with gentle downward traction on the fetal head, requiring additional obstetric maneuvers to effect delivery, as documented by the delivery physician

    Time frame: Delivery

  16. Number of participants with NICU admission

    Admission to the neonatal intensive care unit for any indication in the first 7 days of life

    Time frame: Within 7 days of delivery

  17. Infant adiposity

    Calculated using a flank skinfold

    Time frame: Within 72 hours of delivery

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Scifres CM, Battarbee AN, Feghali MN, Pierce S, Edwards RK, Smith EM, Guise D, Bhamidipalli S, Daggy J, Tuuli MG. Intensive glycaemic targets in overweight and obese individuals with gestational diabetes mellitus: clinical trial protocol for the iGDM study. BMJ Open. 2024 Feb 29;14(2):e082126. doi: 10.1136/bmjopen-2023-082126. PubMed 38423770 ↗

Individual participant data

Plan to share: Yes — Once the study is completed and the investigators have published the main manuscripts regarding the outcomes of the trial, de-identified data will be made available by request. All requests will require review and approval by the investigators and the institutional regulatory committees.

Supporting information: Study protocol

Time frame: Data will be available one year after study completion.

Access criteria: Data access will be possible after approval of the request for data by the primary study team and after appropriate regulatory documents are in place.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 57 months is above that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Nov 18, 2021
StartActual
Mar 1, 2022
Primary completionEst.
Dec 31, 2026was Oct 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Dec 31, 2026
Oct 16, 2026
Contact
Study contact changed: s•••@iu.edu · •••7069→r•••@iu.edu · •••8040. See the current contact
Oct 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Indiana University · Indianapolis, United StatesContact s•••@iu.edu · •••7069→r•••@iu.edu · •••8040
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Oct 1, 2026→Dec 31, 2026
    Contact Study contact changed: s•••@iu.edu · •••7069→r•••@iu.edu · •••8040. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Indiana University · Indianapolis, United StatesContact s•••@iu.edu · •••7069→r•••@iu.edu · •••8040
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05124808
Lead sponsor
Indiana University
Responsible party
Christina Scifres (Professor, Indiana University) — Principal investigator
First posted
Nov 18, 2021
Start date
Mar 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Rasika Sadolikar, MBBS, MPH
Contact
rsadolik@iu.edu
(317)278-8040
Christina Scifres, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion